Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development. The introduction of direct-acting antivirals (DAAs) has revolutionized HCV treatment, achieving high rates of sustained virologic response (SVR) and reducing HCV-associated morbidity and mortality. Despite these advancements, the risk of HCC persists in certain populations, particularly those with pre-treatment cirrhosis or advanced fibrosis (F3). This review examines the impact of DAAs on HCC risk, explores the underlying mechanisms of hepatocarcinogenesis post-HCV eradication, identifies key risk factors, and discusses optimal HCC surveillance strategies.
DAA impact on HCC: Turning the tide on risk reduction
DAA therapy has…